Recent Advances in the Search for Effective Anti-Alzheimer's Drugs

被引:0
|
作者
Ogos, Martyna [1 ]
Stary, Dorota [1 ]
Bajda, Marek [1 ]
机构
[1] Jagiellonian Univ Med Coll, Dept Physicochem Drug Anal, Med Str 9, PL-30688 Krakow, Poland
关键词
Alzheimer's disease; multi-target-directed ligands; beta-amyloid aggregation inhibitors; AChE inhibitors; donepezil; tacrine; BChE inhibitors; neurodegenerative disorders; GLUTAMINYL CYCLASE; DIRECTED LIGANDS; NMDA RECEPTORS; DISEASE; DISCOVERY; BETA; CHOLINESTERASE; DERIVATIVES; INHIBITORS; BIOLOGY;
D O I
10.3390/ijms26010157
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease, the most common form of dementia, is characterized by the deposition of amyloid plaques and neurofibrillary tangles in the brain, leading to the loss of neurons and a decline in a person's memory and cognitive function. As a multifactorial disease, Alzheimer's involves multiple pathogenic mechanisms, making its treatment particularly challenging. Current drugs approved for the treatment of Alzheimer's disease only alleviate symptoms but cannot stop the progression. Moreover, these drugs typically target a single pathogenic mechanism, leaving other contributing factors unaddressed. Recent advancements in drug design have led to the development of multi-target-directed ligands (MTDLs), which have gained popularity for their ability to simultaneously target multiple pathogenic mechanisms. This paper focuses on analyzing the activity, mechanism of action, and binding properties of the anti-Alzheimer's MTDLs developed between 2020 and 2024.
引用
收藏
页数:49
相关论文
共 50 条
  • [21] Anti-alzheimer drugs in adults with Down's syndrome who are clinically dementing
    Brown, SW
    Mathurin, W
    McBrien, J
    Whitwham, S
    Masters, S
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (08): : 1220 - 1220
  • [22] Rational approach to discover multipotent anti-Alzheimer drugs
    Rosini, M
    Andrisano, V
    Bartolini, M
    Bolognesi, ML
    Hrelia, P
    Minarini, A
    Tarozzi, A
    Melchiorre, C
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (02) : 360 - 363
  • [23] Cognition enhancers, anti-Alzheimer and neuroprotective drugs - Introduction
    Scriabine, A
    CNS DRUG REVIEWS, 2000, 6 : 1 - 2
  • [24] A Recent Appraisal of Small-Organic Molecules as Anti-Alzheimer's Agents
    Gupta, Mohan
    Kumar, Avinash
    Ojha, Madhwi
    Khan, Shabana Kausar
    Nain, Sumitra
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (08) : 962 - 976
  • [25] Factors associated with persistence to anti-alzheimer drugs in France
    Pinet, Marion
    Pariente, Antoine
    Merliere, Yvon
    Moride, Yola
    Moore, Nicholas
    Fourrier-Reglat, Annie
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S34 - S35
  • [26] Experimental and clinical methods in the development of anti-Alzheimer drugs
    Allain, H
    Bentue-Ferrer, D
    Zekri, O
    Schück, S
    Lebreton, S
    Reymann, JM
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1998, 12 (01) : 13 - 29
  • [27] Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents
    Ambure, Pravin
    Roy, Kunal
    EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (06) : 697 - 723
  • [28] The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis
    Sugimoto, Hachiro
    CHEMICO-BIOLOGICAL INTERACTIONS, 2008, 175 (1-3) : 204 - 208
  • [29] Donepezil-ferulic acid hybrids as anti-Alzheimer drugs
    Benchekroun, Mohamed
    Ismaili, Lhassane
    Pudlo, Marc
    Luzet, Vincent
    Gharbi, Tijani
    Refouvelet, Bernard
    Marco-Contelles, Jose
    FUTURE MEDICINAL CHEMISTRY, 2015, 7 (01) : 15 - 21
  • [30] Anti-Alzheimer's Drugs: Hepatobiliary Toxicity, Data from the French Pharmacovigilance Database
    Maura, Geric
    Vallet, Catherine
    Nouasria, Imane
    Herlem, Emmanuelle
    Trenque, Thierry
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S307 - S307